A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.
Rafael Grochot(Sarah Cannon Research Institute), J O'Shaughnessy(Texas Oncology), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Anne Armstrong(The Christie NHS Foundation Trust), P. Lorusso(Yale Cancer Center), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Hyo S. Han(Moffitt Cancer Center), Marian Girgis(Henry Ford Health System), Erika P. Hamilton(Sarah Cannon), Hendrik-Tobias Arkenau, Hannah van den Boomen(HRA Pharma (United Kingdom)), V. Boni(Hospital Universitario Quirónsalud Madrid), Carlo Palmieri(Clatterbridge Cancer Centre NHS Foundation Trust), Neelima Vidula(Harvard University)
Cited by 0
Related Papers
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
|The Lancet|2019|287
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77